Data from KEYNOTE-555 cohort B suggest consistent benefit-risk profile and similar overall response rate (ORR), PFS, and AEs in a pembrolizumab 400 mg Q6W dosing regimen compared to a 200 mg Q3W dosing in advanced melanoma.10 A recent retrospective study showed that there was no OS difference in patients with stage IV NSCLC and PD-L1 TPS ≥ 50% who were treated with first-line pembrolizumab and dosed at Q3W or Q6W intervals, based on a 2:1 case-matched analysis. Here, CD274 is linked to non-small cell lung carcinoma.